Document is current

Article History

Received: 7 August 2018

Accepted: 24 September 2018

First Online: 1 October 2018

Ethics approval and consent to participate

: Informed written consent was obtained from each patient before conducting any procedures. Additional information on the study was provided verbally by the study investigator or in a written format. The study protocol was reviewed by the Independent Ethics Committee or Institutional Review Board for each centre. The study was conducted according to the ethical principles of the Declaration of Helsinki.

: Not applicable

: <b>TS</b> is a consultant for Alder, Allergan, Amgen, ATI, Avanir, Dr. Reddy’s, Ipsen Bioscience, Lilly, Nocira, Novartis, and Teva, serves on the Board of Directors of the American Headache Society and the Board of Trustees of the International Headache Society, receives royalties from UpToDate, and owns stock options in Aural Analytics, Nocira and Second Opinion. <b>UR</b> reports research grants from BMBF and Pharm Allergan; consulting fees from Amgen, Autonomic Technologies, Novartis, Eli Lilly, and CoLucid; is on speakers’ bureaus for Amgen, Novartis, Eli Lilly, CoLucid, Pharm Allergan, and Teva; on advisory boards for Amgen, Autonomic Technologies, Novartis, and Pharm Allergan; and serves on the editorial board of Frontiers in Neurology; UR is a member at large of the EHF. <b>ST</b> reports research grants (no personal compensation) from Alder, Allergan, Amgen, Dr. Reddy’s, Scion Neurostim, Teva, and Zosano; consulting fees from Acorda, Alder, Alexsa, Allergan, Amgen, ATI, Cefaly, Avanir, Charleston Laboratories, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, GLG, Guidepoint Global, Impax, Neurolief, Pfizer, Scion Neurostim, Slingshot Insights, Supernus, Teva, Zosano royalties from Springer; holds non-remunerative positions of influence on the board of the American Headache Society; stock options in ATI; is an employee of Dartmouth-Hitchcock Medical Center; and a salaried editor at the American Headache Society. <b>AM</b> is a consultant or scientific advisor for Allergan, Amgen, Alder, ATI, Eli Lilly, Novartis and Teva. <b>DK</b> is a consultant for Eli Lilly & Co., Amgen Inc., and Alder. <b>GB</b> has received research grants from ÖGN, ÖAW and EHF, consulting fees from Novartis, Pfizer, Allergan, Reckitt Benckiser, and serves on speaker bureaus for Amgen, Novartis, Pfizer, Allergan, Reckitt Benkiser, Teva and Linde AG. <b>GPB</b> receives research support from Amgen, TEVA, Eli Lilly, Allergan, and honoraria from Allergan. <b>PM</b> reports research grants from Amgen, Eli Lilly, Teva, and Alder; and consulting fees from Amgen. <b>TV, FZ, SC, HP,</b> and <b>DM</b> are employees and stockholders of Amgen. <b>SW, JK</b> and <b>JK</b> are employees and stockholders of Novartis.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.